Polpharma Biologics anuncia que la FDA y la EMA han aceptado la revisión del candidato a biosimilar PB016 de vedolizumab

Your ads will be inserted here by

Easy Plugin for AdSense.

Please go to the plugin admin page to
Paste your ad code OR
Suppress this ad slot.